After two headline successes, companies rush to develop “smart bomb” cancer drugs.
The Scientist
Most Recent
Understanding the mechanism of a classic tuberculosis treatment could refine future strategies for TB drug development.
Reinvestigating a natural antibiotic compound reveals its potential as a tuberculosis drug.
A cheap pain reliever that can kill drug-resistant, tuberculosis-causing bacteria may never be tested.
Doctors question whether a government initiative to speed approval for promising new drugs is ensuring safety.
A phylogenetic study of traditional plant remedies could aid drug development.
A human trial of a hepatitis C treatment is shut down after one of the participants died.
The market for drugs that target rare diseases is expected to rival big pharma blockbusters in the coming decades.
A small molecule that inhibits a protein important for chromatin organization can cause reversible sterility in male mice.
A former manager at Genentech claims the company bypassed ethical and clinical guidelines in order to rush a promising drug through clinical trials.
Follow The Scientist
Advertisement
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Current Issue
